We find that CD69 and SBK1 are differentially expressed in cancer patients who respond to PD-1/PD-L1 blockade when compared with non-responders, and that they are potential biomarkers of response to PD-1/PD-L1 blocking cancer immunotherapy. This evidence concerns the gene PDCD1 and cancer.